Outsourcing: Analysis and developments of contract service providers to the pharmaceutical and biotechnology industries - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe
Outsourcing
Contract manufacturing organizations (CMOs) and contract research organizations (CROs). Global sourcing of pharma ingredients and services. Trends and challenges for the biopharmaceutical and pharmaceutical industries.
« Previous
1234567891011121314151617181920212223
Next »

Stability Program Management

November 2, 2012
By: Deni Jo Williams
Pharmaceutical Technology

To support global stability practices, fundamental basics must be in place.

Advice for Enhancing the Client–Sponsor Relationship

November 2, 2012
By: Susan J. Schniepp
Pharmaceutical Technology

Key talks from the recent PDA/FDA regulatory conference highlight room for improvement.

Patheon to Acquire Banner Pharmacaps

October 31, 2012
By: Stephanie Sutton

Patheon will acquire softgel-specialist company Banner Pharmacaps, based in North Carolina in the US, for $255 million

Considerations for Outsourcing Stability Storage

October 17, 2012
Equipment and Processing Report

Consider the time and expertise needed to maintain regulatory compliance and perform stability testing.

Challenges in Topical Drug Manufacturing

October 17, 2012
By: Michael Lowenborg
Equipment and Processing Report

Consider these tools and strategies for optimizing the manufacturing process.

Partnerships Remain Crucial to Future Development

October 2, 2012
By: David Mitchell
Pharmaceutical Technology

Working together affords many unseen opportunities for pharmaceutical innovation.

Sizing the Market for Contract Manufacturing

October 2, 2012
By: Jim Miller
Pharmaceutical Technology

Measuring the size of the market for contract manufacturing services requires a careful hand.

Outsourcing Pharmaceutical Infrastructure Operations

October 2, 2012
By: Mel Palmer, David Lyons
Pharmaceutical Technology

Today's pharmaceutical companies are striving to reduce costs and maximize efficiencies, and must make decisions on the best way to deploy their limited resources.

The Macro View

September 2, 2012
By: Jim Miller
Pharmaceutical Technology

The weak global economy adds to the challenges of bio/pharma companies and their suppliers.

« Previous
1234567891011121314151617181920212223
Next »

ADVERTISEMENT
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
21%
To all process for new products only
11%
To select process for new products only
25%
To select processes for both new and legacy products
21%
Do not use QbD
23%
View Results
Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
FindPharma Custom Search
Featured Jobs

More Jobs
Click here